RHYTHM AI Reports Publication of STAR Mapping Clinical Outcome Study

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

January 26, 2021

RHYTHM AI Ltd, a UK company focused on the treatment of Atrial Fibrillation (AF), today announces the publication of a clinical outcome study for its STAR (Stochastic Trajectory Analysis of Ranked signals) Mapping system, which is designed to improve outcomes in patients receiving ablation treatment for persistent AF.

The article in the peer-reviewed journal, Journal of Cardiovascular Electrophysiology is titled “Ablation guided by STAR Mapping, in addition to pulmonary vein isolation, is superior to pulmonary vein isolation alone or in combination with CFAE/linear ablation for persistent AF”.*

Patients undergoing Pulmonary Vein Isolation (PVI) plus STAR guided ablation (STAR cohort) was compared to a propensity-matched cohort undergoing PVI and Complex Fractionated Atrial Electrogram (CFAE) and/or linear ablation (conventional ablation cohort). The STAR cohort was also compared to a cohort of patients undergoing PVI only ablation (PVI alone ablation cohort).

Key highlights from the study:

  • The AF termination rates were significantly higher in the STAR cohort compared to both the conventional ablation cohort and the PVI alone ablation cohort.
  • During ≥20 months follow-up a lower proportion of patients had AF/AT recurrence in the STAR cohort when compared to the conventional ablation cohort or the PVI alone ablation cohort.
  • The number of patients undergoing a repeat procedure during the follow-up period was significantly lower in the STAR cohort when compared to the conventional ablation cohort and the PVI alone ablation cohort.
  • Performance of the PVI alone and conventional patient cohorts were in line with expectations based on other published studies.**
  • 65 patients were studied in the STAR cohort.
  • 65 patients were studied in the conventional ablation cohort.
  • 50 patients were studied in the PVI alone ablation cohort.
  • STAR vs. conventional ablation:

o    Success (freedom from AF/AT) after a single procedure was 80% (52/65) in the STAR cohort, compared to 49.2% (32/65) in the conventional ablation cohort (p<0.001).

o    Rates of recurrent AF (excluding Atrial tachycardia) were 4/65 (6.2%) with STAR, compared to 26/65 (40%) with conventional ablation (p<0.001).

o    Follow-up period was longer in the STAR cohort (29.5±3.7 months vs. 20.5±8.1 months; p<0.001).

  • STAR vs. PVI alone ablation:
    • Success (freedom from AF/AT) after a single procedure was significantly higher in the STAR cohort when compared to the PVI alone ablation cohort (80% (52/65) vs 50% (25/50); p=0.001).
    • Rates of recurrent AF (excluding Atrial tachycardia)4/65 (6.2%) in the STAR cohort, compared to 22/50 (44.0%) in the PVI alone ablation cohort (p<0.001).
    • Follow-up period was longer in the STAR cohort (29.5±3.7 months vs. 22.6±5.8 months; p<0.001).

Simon Hubbert, Chief Executive of RHYTHM AI Ltd, commented: “We are encouraged to see additional, positive data demonstrating the superior results of STAR Mapping in the treatment of persistent AF,  that has historically proved difficult to treat with conventional ablation therapy.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.